Abstract
Background
Large Cell Neuroendocrine Carcinoma of the Lung (L-LCNEC) is a rare type of neuroendocrine lung cancer that is increasingly diagnosed. However, the optimal management regarding the advanced stage is unclear. The purpose of this article is to present and compare our experience when L-LCNEC is treated as Small Cell Lung Cancer (SCLC).
Patients and Methods
Overall, eight cases of L-LCNEC were included. We retrospectively reviewed medical files and reports by accessing the Institution's Data of patients diagnosed with L-LCNEC from April 2019 until December 2020 and evaluated their response to the combination of Platinum – Etoposide – Atezolizumab as first-line chemotherapy.
Results
The overall observed response rate (ORR) of 75%. The median PFS was 6.85 months. The median response duration was 5.5 months.
Conclusions
Comparing our findings with other retrospective and prospective studies, it seems that the systematic treatment of choice and management in L-LCNEC of the lung should be that of a small cell carcinoma of the lung.
Ethics approval
Ethical approval was granted by the Ethics Committee of the Bank of Cyprus Oncology Centre. Consent was obtained from patients. This study complies with our institutions and country's requirements regarding ethics approval. This study was performed in accordance with the Declaration of Helsinki.
Disclosure statement
No potential competing interest was reported by the author(s).
Funding information
No funds, grants, material, or other support was received. The authors have no financial or proprietary interests in any material discussed in this article.
Data availability statement
The datasets generated and analyzed during the current study are not publicly available. These data were obtained from the Institution's database and are available from the corresponding author on reasonable request.